Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants-Reference-Cited by-同舟云学术

Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants

Published:2024-05-22 Issue:2 Volume:24 Page:179-186
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Park Jin-Woo,Chung Hyewon,Kim Jong-Min,Kim Na Young,Hong Sung Hee,Kim Kyoung-Ah,Park Ji-Young

Funder

Hanmi Pharmaceutical Co., Ltd

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40268-024-00460-y.pdf

Reference27 articles.

1. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310:591–608. https://doi.org/10.1001/jama.2013.13805.

2. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Tria l Research Group. Arch Intern Med. 1992;152:56-64.

3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60. https://doi.org/10.1016/S0140-6736(12)61766-8.

4. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–115. https://doi.org/10.1161/HYP.0000000000000065.

5. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Euro Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.